Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies

Area of Science:

• Neurogenetics
• Neurodegenerative Diseases
• Molecular Biology

Background:

• Huntington's disease (HD) is a fatal monogenic neurodegenerative disorder caused by expanded CAG repeats in the huntingtin (HTT) gene.
• HD manifests with progressive motor, cognitive, and behavioral symptoms, leading to significant disability and reduced lifespan.
• Genetic testing enables early diagnosis and identification of mutation carriers before symptom onset.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Huntington's disease.
• To highlight the importance of novel tools for evaluating disease-modifying therapies.
• To discuss the potential impact of these advancements on clinical trial design and patient outcomes.

Main Methods:

• Review of current literature on Huntington's disease pathogenesis and therapeutic development.
• Analysis of emerging treatment modalities, including protein-lowering strategies.
• Discussion of the need for advanced biomarkers and sensitive clinical rating scales.

Main Results:

• Several therapeutic approaches targeting HTT protein lowering are in development, including antisense oligonucleotides (ASOs), RNA interference, and small-molecule modulators.
• ASO and RNA interference therapies are further advanced, while others are in preclinical stages.
• Novel biomarkers and sensitive clinical scales are essential for assessing treatment efficacy and disease progression.

Conclusions:

• HTT protein-lowering therapies represent a promising frontier for treating Huntington's disease, potentially offering the first disease-modifying treatment.
• Development of sensitive biomarkers and rating scales is critical for the successful evaluation of these novel therapies in clinical trials.
• These advancements are vital for targeting the earliest stages of HD, including the prodromal and phenoconversion periods.